#### **CORRECTED VERSION**

# (19) World Intellectual Property Organization

International Bureau

(43) International Publication Date 5 February 2004 (05.02.2004)



### 

**PCT** 

## (10) International Publication Number WO 2004/011487 A3

- (51) International Patent Classification<sup>7</sup>: C07K 7/54, 7/64, A61K 38/12, G01N 33/68
- (21) International Application Number:

PCT/IT2003/000446

- (22) International Filing Date: 18 July 2003 (18.07.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

- (30) Priority Data: RM2002A000402 29 July 2002 (29.07.2002) IT
- (71) Applicant (for all designated States except US): SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. [IT/IT]; 47, Viale Shakespeare, I-00144 Rome (IT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DAL POZZO, Alma [IT/IT]; c/o Istituto Scientifico "G. Ronzoni", Via Colombo, 81, I-20133 Milano (IT). GIANNINI, Giuseppe [IT/IT]; Sigma-Tau Industrie Farmaceutiche, Riunite S.p.a., Via Pontina, km 30, 400, I-00040 Pomezia (IT). PISANO, Claudio [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche, Riunite S.p.A., Via Pontina Km. 30,400, I-00040 Pomezia (IT).
- (74) Agents: SPADARO, Marco et al.; Cavattoni-Raimondi, Viale dei Parioli, 160, I-00197 Roma (IT).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- (88) Date of publication of the international search report:
  18 March 2004
- (48) Date of publication of this corrected version:

16 December 2004

(15) Information about Correction: see PCT Gazette No. 51/2004 of 16 December 2004, Sec-

see PCI Gazette No. 51/2004 of 16 December 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(57) Abstract: Compounds of formula (I) cyclo [NX<sub>1</sub>-R<sub>1</sub>-CO-NX<sub>2</sub>-R<sub>2</sub>-CO-NX<sub>3</sub>-R<sub>3</sub>-CO-NX<sub>4</sub>-CO-NX<sub>5</sub>-R<sub>5</sub>-CO], wherein at least one x-fluoroalkylated amino acid is present, are inhibitors of integrins, particularly those belonging to the  $\alpha_{\nu}\beta_{3}$  and  $\alpha_{\nu}\beta_{5}$  family, and thus are useful as medicaments, particularly for the treatment of the underlying diseases responsible for abnormal angiogenesis, such as retinopathy, acute kidney failure, osteoporosis and metastases. The compounds described herein are also useful as diagnostic agents, when appropriately labelled, especially for the detection and location of small tumour masses and arterial occlusion events.

